AGL
agilon health, inc. (AGL) Economic Moat Analysis (2026)
Overall Score
Pricing Power
Gross margin is effectively zero at 0.001% TTM, indicating no meaningful pricing power.
Negative EBIT margin of -4.4% and net margin of -4.2% show the business is not converting revenue into profit.
Scale Efficiency
Asset turnover is high at 3.72x and fixed asset turnover is 201.4x, suggesting efficient use of assets.
However, the very low gross margin and negative operating margin indicate scale is not translating into durable operating leverage.
Customer Stickiness
Days of sales outstanding at 65.3 and cash conversion cycle at 48.4 days suggest moderate working-capital friction.
No evidence in the current metrics of recurring revenue or retention strength.
Cost Advantage
SG&A is only 4.4% of revenue, which points to a lean cost structure.
That said, negative operating cash flow and negative free cash flow indicate the cost base is still not producing durable economic advantage.
Intangible Assets Switching Costs
Intangibles are only 3.8% of total assets, implying limited balance-sheet support for moat-like intangibles.
No fresh news indicates patents, brand expansion, or switching-cost reinforcement.
Network Effects Ecosystem
No evidence of network effects or ecosystem-driven monetization in the current data.
The business appears to compete on execution rather than platform dynamics.
Capital Efficiency
ROIC is deeply negative at -90.2% and ROE is -119.3%, showing poor capital efficiency.
Free cash flow is negative and EV/FCF is -14.2x, reinforcing the lack of economic surplus generation.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on agilon health, inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

